Defective Natural Immunity: An Early Manifestation of Human Immunodeficiency Virus Infection

By Henrik Ullum,* Peter C. Gøtzsche,* Jette Victor,* Ebbe Dickmeiss,† Peter Skinhøj,* and Bente Klarlund Pedersen*

From the *Department of Infectious Diseases and †Department of Clinical Immunology, Rigshospitalet, The National University Hospital, 2200 Copenhagen N, Denmark

Summary

Cytotoxicity mediated by natural killer (NK) and lymphokine-activated killer (LAK) cells may be of significance in host defense against viral infections. This study included 347 patients infected with human immunodeficiency syndrome virus (HIV) type 1 and 110 controls. The NK cell activity, either unstimulated or stimulated with interferon-α (IFN-α) or interleukin-2 (IL-2), and the LAK cell activity were suppressed in patients, but the NK/LAK cell activity did not differ between patients with AIDS and patients without AIDS. However, the IFN-α-stimulated NK cell activity and LAK cell activity were reduced in patients with symptoms of HIV disease (CDCIV) when compared with asymptomatic patients (CDCII + III). When the data were analyzed by multiple linear regression, the percentage of CD4+ cells had a positive effect on these two parameters in patients without AIDS, whereas the percentage of CD4+ cells had no significant effect on unstimulated and IL-2-stimulated NK cell activity in these patients. In controls and AIDS patients, the percentage of CD4+ cells had no effect on NK/LAK cell activity in multiple linear models. The total number of CD16+ cells was low in patients compared to controls, whereas the percentages of CD16+, CD56+, and CD16+CD56+ were either normal or elevated. Therefore, the decrease in NK cell subpopulations did not contribute to the observed depression in NK/LAK cell activity in vitro. It is concluded that natural immunity is suppressed in HIV-seropositive patients primarily because of a qualitative defect of the NK/LAK cells. This qualitative defect includes a reduced responsiveness to IFN-α, which is progressive until the onset of symptoms, and possibly related to the loss of CD4+ cells.

Infection with HIV type 1 causes progressive immunosuppression (1–3). This includes suppression of the natural immunity mediated by NK cells (4–12) and their in vitro counterparts, LAK cells (13–17).

NK cells are CD3− large granular lymphocytes that express characteristic NK cell markers such as CD16 and CD56; a subpopulation expresses CD8 (18). They mediate non-MHC-restricted cytotoxicity and offer potential resistance to viral opportunistic infections mediated by EBV, CMV, herpes simplex, and herpes zoster virus (19). They also mediate cytotoxic activity against malignant cells and may mediate resistance against AIDS-associated tumors such as Kaposi’s sarcoma (18). The in vitro–generated LAK cells show a broader range of non–MHC-restricted target killing (20).

The clinical significance and the mechanism of HIV-induced loss of natural immunity are not fully understood. The impaired NK cell activity is observed on the clonal level and is related to defects both at the target and postbinding levels (5). It is not clear whether the suppressed NK and LAK cell activity in HIV-seropositive subjects is caused by mainly low percentage, altered phenotypic appearance, or decreased function of NK cells (6, 10, 12).

The aim of this study was by use of a large study material to test whether NK and LAK cell activity were related to (a) expression of NK cell related cell markers; (b) prognostic markers of HIV infection; and (c) clinical outcome (judged by occurrence of AIDS and presence of herpes virus infections and malignancy).

Materials and Methods

Patients. 347 HIV-infected patients agreed to participate in the study; 308 (86%) were male and the median age was 39 yr (quartiles = 33–47 yr). Of all the patients, 266 were homo- or bisexual males, 54 were infected through heterosexual contact, 9 were drug addicts, 6 were hemophiliacs, 10 were infected by blood transfusions, and 9 had unknown risk factors (7 patients had more than one risk factor). 110 (32%) patients had AIDS, AIDS-defining symptoms were Pneumocystis carinii pneumonia (PCP) in 55 patients, candidiasis of the esophagus, trachea, bronchi, or lungs in 26, Kaposi's
sarcoma in 26, toxoplasmosis of the brain in 19, cytomegalovirus infection in 11, HIV wasting syndrome in 8, disseminated atypical mycobacteriosis in 6, and other AIDS-defining events in 23. Patients were further subclassified by use of The Center for Disease Control (CDC) system of classification. 132 asymptomatic patients were classified into CDC group II and CDC group III (CDCII + III), whereas 215 patients with symptoms related to HIV infection were classified to CDC group IV (CDCIV). A control group of 110 HIV-seronegative subjects (89% males) not at risk for HIV infection with a median age of 39 yr (quartiles = 33-49 yr) was used for comparison.

Blood Sampling and Isolation of Blood Mononuclear Cells (BMNC). 60 ml of blood was drawn from each subject and BMNC were isolated by density gradient centrifugation (Lymphoprep; Nyegaard, Oslo, Norway) on LeucoSep tubes (Greiner, Frickenhausen, Germany) and washed three times in medium RPMI 1640 (GIBCO BRL, Gaithersburg, MD). Cells were frozen in freezing medium (50% RPMI, 30% FCS [GIBCO BRL], 20% DMSO [Bie & Berntsen, Redovre, Denmark]) and were kept in liquid nitrogen until thawed for analysis.

Some patients had so few cells that it was impossible to analyze all of the immune markers.

Determination of NK Cell Activity. NK cell activity was measured using K562 target cells in a 51Cr release assay. BMNC were thawed and incubated for 1 h at 37°C with: (a) medium; (b) 10^6 IU/ml IFN-α (kindly provided by Dr. Robert Jordal, The Blood Bank, Copenhagen County Hospital, Gentofte, Denmark); (c) 20 IU/ml IL-2 (Boehringer Mannheim GmbH, Mannheim, Germany). Triplettes of 100 µl effector cells in their incubation medium and 100 µl target cells (10^5 cells per ml) were incubated in microtiter plates for 4 h at 37°C. Unstimulated effector cells were added in different concentrations, E/T ratios of 100:1, 50:1, 25:1, and 12.5:1, whereas IL-2- and IFN-α-stimulated effector cells were used at an E/T ratio of 50:1. The plates were centrifuged for 10 min; 100 µl supernatant was transferred to new tubes and radioactivity was determined. Spontaneous release was determined by incubation of 100 µl target cells with 100 µl medium and maximum release by incubation of 100 µl target cells plus 100 µl medium with 10% Triton X-100. Percentage of 51Cr release (NK cell activity) was determined by the equation

\[
\text{percent of lysis} = \frac{(\text{test-spontaneous})\text{cpm}}{\text{(maximum-spontaneous})\text{cpm}} \times 100,
\]

and was given as mean of triplicates. For subjects with NK cell activity >5% (214 patients, 91 controls) lytic units (LU15) were calculated. One LU15 is the number of effector cells required to achieve 15% cytotoxicity of K562 as derived from a titration curve of twofold serial dilutions of effector cells. One LU15/10^6 CD16^+ cells is the number of LU15 in 10^6 CD16^+ cells. In each assay, three preparations of cryopreserved BMNC obtained from buffy coats were also analyzed. Whenever two out of three control preparations were outside their normal range (mean ± 2 SD), the assay was rejected. On average, 51Cr spontaneous release never exceeded 15% and was 8% of maximum release. Three controls and six patients (three non-AIDS, three AIDS) had NK cell activity measured by use of fresh and frozen BMNC of the same blood sample. Frozen cells had in general a slightly reduced cytotoxic activity; the effect differed between assays, whereas the relative decrease was similar in patients and controls (data not shown).

Results

NK and LAK Cell Activity. Unstimulated NK cell activity expressed at E/T ratios of 100:1, 50:1, 25:1, or 12.5:1 was measured in a 51Cr release assay using DAUDI target cells. 100 µl LAK cell suspension and 100 µl target cells (2x10^4 cells per ml) were added to each well in microtitre plates. LAK cells were added in different concentrations giving E/T ratios of 50:1, 25:1, 12.5:1, and 6.25:1. Otherwise the 51Cr release assay was performed as described for the NK cell assay. Cryopreserved control preparations were made and used as already described. On average, the spontaneous release of 51Cr never exceeded 25% and was 11% of maximum release.

Clinical Chemical Tests. Leukocyte, lymphocyte, and neutrophocyte concentrations were determined using a cell counter (Technicon H.I.; Miles Inc., Tarrytown, NY). Antibodies to HIV were assessed using an ELISA and confirmed by the Western blot method. HIV-24 antigen was detected with a sandwich-type immunoassay that used murine mAb (anti-HIV core antigen) coated onto microwell strips (Coulter Corp., Hialeah, FL). Serum β2-microglobulin concentrations were measured with a quantitative competitive enzyme (Pharmacia Diagnostics, Piscataway, NJ).

FACS® Analysis. PE-conjugated mAbs IgG1, Leu-2a (CD8), Leu-M3 (CD14), and Leu-19 (CD56) (Becton Dickinson and Co., Mountain View, CA) and fluorescein-conjugated mAbs IgG1, Leu-4 (CD3), Leu-2 (CD4), and Leu-11a (CD16) (Becton Dickinson) were used. Frozen mononuclear cells were thawed and washed twice in PBS with 2% FCS. 10^6 cells were resuspended in 100 µl PBS containing FCS and incubated for 30 min at 5°C with 10 µl of one or two mAbs. Labeled cells were washed three times and analyzed by flow cytometry using a FACSStar® (Becton Dickinson). The mononuclear cells were incubated with antibodies to CD16 in combination with CD8 and CD16 in combination with CD6. PE- and fluorescein-conjugated mouse IgG1 was used as a negative control. Lymphocytes were distinguished from monocytes by their forward vs right angle light scatter. The monocyte-specific reagent CD14 was used to test for monocyte contamination of lymphocytes. On average, the proportion of CD14^+ cells within the lymphocyte gate was 2.6% for the patient group and 1.7% for controls. In patients, fresh and frozen BMNC were independently analyzed for expression of CD4. Three controls and three patients had a complete FACS® (Becton Dickinson) analysis performed on fresh and frozen cells. Freezing did not change the composition of lymphocyte subsets in neither group (data not shown).

Statistical Analysis. Since the data did not have a normal distribution, they are presented as medians, 1. and 3. quartiles. Groups were compared by rank sum tests with P = 0.05 as the significance level. Initially, NK/LAK cell activity was compared between groups at an E/T ratio of 50:1, and only if this was significant, other E/T ratios were compared. Correlations and multiple linear regression were used to examine relations between different markers within each group. BMDP (Los Angeles, CA) and SYSTAT (Evanston, IL) statistical software were used.

**Abbreviations used in this paper:** BMNC, blood mononuclear cells; CDC, Center for Disease Control; LU15: lytic units.
patients who had and had not developed Kaposi's sarcoma, lymphoma, or herpes virus infections (data not shown).

The LAK cell activity was lower in patients than in controls ($P < 10^{-9}$ in all E/T ratios), but no difference was found between patients with AIDS and patients without AIDS ($P = 1$ at an E/T ratio of 50:1; Fig. 2). Patients in CDCIV had lower LAK cell activity in E/T ratio 50:1 and E/T ratio 25:1 compared to patients in CDCII + III (Table 1). NK cell activity stimulated by IL-2 or IFN-α was reduced in patients compared to controls, whereas patients with AIDS had similar activity as patients without AIDS (Table 2). It also appears from Table 2 that the NK cell activity evaluated by percentage of lysis of target cells was boosted with IL-2 to the same extent in patients and controls, whereas there was an impaired

Table 1. Comparison of NK Cell and LAK Cell Activity between CDC Groups

|                   | CDCII + III ($n = 132$) | CDCIV ($n = 215$) | Comparison of groups |
|-------------------|--------------------------|-------------------|---------------------|
| NK cell activity (percentage of lysis) |                          |                   |                     |
| Unstimulated (E/T = 50:1) | 9 (4-16)                 | 8 (4-13)          | $P = 0.2$           |
| IL-2 stimulated (E/T = 50:1) | 16 (7-25)                | 13 (6-22)         | $P = 0.08$          |
| Difference (Stimulated-unstimulated) | 5 (0-11)                 | 3 (1-9)           | $P = 0.3$           |
| IFN-α stimulated (E/T = 50:1) | 17 (7-25)                | 12 (6-19)         | $P = 0.02$          |
| Difference (Stimulated-unstimulated) | 6 (2-10)                 | 3 (0-7)           | $< 0.0001$          |
| LAK cell activity (percentage of lysis) |                          |                   |                     |
| (E/T) = 50:1 | 33 (19-46)               | 24 (12-42)        | $P = 0.02$          |
| LAK cell activity (percentage of lysis) (E/T) = 25:1 | 24 (12-42) | 22 (9-34) | $P = 0.05$ |

Median, quartiles, and $P$ values are shown.
IFN-α boosting of NK cell activity in the patients. Patients in CDCIV had reduced IFN-α-stimulated NK cell activity when compared to patients in CDCII+III, whereas the IL-2-stimulated NK cell activity did not differ between these two subgroups (Table 1).

Lymphocyte Subpopulations. The percentages of CD16+ and CD16+CD56+ cells did not differ between patients and controls (P = 0.3 vs P = 0.2), but the percentages of CD56+ and CD16+CD8+ NK cell subtypes were higher in patients compared to controls (P <0.0001). The percentage of CD16+CD8+ cells did not differ between patients with AIDS and patients without AIDS (P = 0.3), but the percentages of all other NK cell subtypes were higher in the AIDS group compared to the non-AIDS group (P <0.0001).

The total concentrations of CD16+ and CD16+56+ cells were lower in patients compared to controls (P = 0.0007 vs P = 0.0003), whereas the total concentration of CD56+ cells did not differ between patients and controls (P = 1.0) and the concentration of CD16+CD8+ cells was elevated in the patient group (P = 0.0004). The total concentrations of all NK cell subsets were suppressed in the AIDS group compared to the non-AIDS group (Table 3).

The percentage and absolute number of CD8+ cells were elevated in patients compared to controls. There was a slight increase in the percentage of CD8+ cells in the AIDS group compared to the non-AIDS group, whereas the total number of CD8+ cells was twofold increased in the non-AIDS group compared to the AIDS group (Table 3). The percentage of CD3+ cells did not differ between patients and controls, whereas the total concentration of CD3+ cells was lower in

Table 2. Analysis of IL-2- and IFN-α-stimulated NK Cell Activity

|                  | (C) | (P) | (N) | (A) | C vs P   | N vs A |
|------------------|-----|-----|-----|-----|----------|--------|
| NK cell activity |     |     |     |     |          |        |
| (percentage of lysis) | 25  | 14  | 13  | 16  | P <0.0001 | P = 0.09 |
| (IL-2 stimulated) | (11–36) | (6–23) | (6–22) | (8–26) |       |        |
| Difference        | 5   | 4   | 4   | 5   | P = 0.61 | P = 0.21 |
| (Stimulated–unstimulated) | (0–13) | (1–10) | (0–10) | (1–12) |       |        |
| NK cell activity |     |     |     |     |          |        |
| (percentage of lysis) | 33  | 13  | 13  | 15  | P <0.0001 | P = 0.06 |
| (IFN-α stimulated) | (21–47) | (6–24) | (6–24) | (11–19) |       |        |
| Difference        | 15  | 4   | 5   | 3   | P <0.0001 | P = 0.11 |
| (Stimulated–unstimulated) | (9–21) | (1–8) | (1–9) | (0–6) |       |        |

Median, quartiles, and P values are shown. All NK/LAK cell activities are at E/T ratio 50:1. C, controls; P, patients; N, non-AIDS; A, AIDS.

Figure 2. LAK cell activity. Percentage of Cr release of K562 target cells at E/T ratios 50:1, 25:1, 12.5:1, and 6.25:1. Controls, n = 94; patients, n = 258; non-AIDS, n = 201; AIDS, n = 57. *Significantly different from controls (P <10−9).
Table 3. Analysis of Lymphocyte Subpopulations

|       | C   | P   | N   | A   | Comparison of groups | Correlation to percent of CD4+ (P only) |
|-------|-----|-----|-----|-----|----------------------|----------------------------------------|
|       | (n = 106) | (n = 325) | (n = 223) | (n = 102) |                    |                                        |
| CD 16+|     |     |     |     |                      |                                        |
| Percentage | 9.1 | 10.0 | 9.3 | 12.0 | P = 0.3             | P = 0.006                               |
|         | (6.6-13.7) | (6.6-15.9) | (6.1-14.9) | (8.0-17.5) |                      |                                        |
| Concentration | 179 | 120 | 149 | 90  | P = 0.0007          | P <0.0001                               |
| (cells per mm³) | (103-271) | (73-230) | (89-258) | (44-155) |                      |                                        |
| CD56+ |     |     |     |     |                      |                                        |
| Percentage | 6.1 | 8.9 | 8.3 | 10.7 | P <0.0001           | P = 0.0003                               |
|         | (4.1-9.7) | (5.7-14.1) | (5.4-12.9) | (7.4-17.3) |                      |                                        |
| Concentration | 115 | 114 | 129 | 74  | P <0.0001           | P = 0.0001                               |
| (cells per mm³) | (69-169) | (55-208) | (73-220) | (36-190) |                      |                                        |
| CD16+CD56+ |     |     |     |     |                      |                                        |
| Percentage | 2.4 | 2.9 | 2.5 | 3.6  | P = 0.2             | P = 0.002                               |
|         | (1.1-4.4) | (1.2-5.2) | (1.0-4.9) | (1.7-6.4) |                      |                                        |
| Concentration | 41  | 33  | 38  | 23  | P = 0.003           | P = 0.006                               |
| (cells per mm³) | (21-88) | (13-71) | (17-75) | (9-61)  |                      |                                        |
| CD16+CD8+ |     |     |     |     |                      |                                        |
| Percentage | 0.7 | 1.6 | 1.5 | 1.7  | P <0.0001           | P = 0.3                                 |
|         | (0.3-1.4) | (0.9-2.9) | (0.9-2.7) | (0.9-3.4) |                      |                                        |
| Concentration | 13  | 21  | 23  | 12  | P <0.0001           | P <0.0001                               |
| (cells per mm³) | (5-25) | (9-40) | (13-47) | (5-29)  |                      |                                        |
| CD8+  |     |     |     |     |                      |                                        |
| Percentage | 22.2 | 42.6 | 40.9 | 46.9 | P <0.0001           | P = 0.02                                |
|         | (17.5-26.8) | (33.1-53.1) | (33.0-50.7) | (33.9-57.0) |                      |                                        |
| Concentration | 386 | 531 | 633 | 310 | P <0.0001           | P <0.0001                               |
| (cells per mm³) | (255-562) | (346-831) | (434-915) | (157-556) |                      |                                        |
| CD3+  |     |     |     |     |                      |                                        |
| Percentage | 62.0 | 62.8 | 64.8 | 56.4 | P = 0.6             | P = 0.0001                              |
|         | (50.2-69.5) | (51.8-71.9) | (54.0-72.4) | (45.0-69.4) |                      |                                        |
| Concentration | 1,077 | 810 | 1,002 | 390 | P <0.0001           | P <0.0001                               |
| (cells per mm³) | (826-1421) | (468-1236) | (681-1364) | (230-630) |                      |                                        |
| CD4+  |     |     |     |     |                      |                                        |
| Percentage | 37.9 | 13.7 | 17.9 | 3.7   | P <0.0001           | P <0.0001                               |
|         | (31.0-42.2) | (4.5-23.0) | (11.9-25.0) | (2.1-8.5)  |                      |                                        |
| Concentration | 677 | 190 | 286 | 34  | P <0.0001           | P <0.0001                               |
| (cells per mm³) | (496-925) | (46-363) | (170-462) | (11-66)  |                      |                                        |

continued
Table 3. Continued

|          | C (n = 106) | P (n = 325) | N (n = 223) | A (n = 102) | Comparison of groups | Correlation to percent of CD4\(^1\) |
|----------|-------------|-------------|-------------|-------------|----------------------|-------------------------------------|
|          |             |             |             |             | C vs P | N vs A | P vs C vs P | N vs A | P vs C vs P | N vs A |
| CD4\(^*\) |             |             |             |             |         |         | <0.001     | <0.001 |         | <0.001 |
| Percentage | ND         | 14.0        | 18.0        | 3.0         | ND      | P        | ND         | P        | ND      | P        |
| (4.5-23.0) | (13.0-26.0) | (1.0-7.5)   |             |             |         |         |            |          |         |          |
| Concentration | ND       | 200         | 286         | 21          | ND      | P        | ND         | P        | ND      | P        |
| (cells per mm\(^3\)) | (38-369) | (180-456)   | (7-54)      |             |         |         |            |          |         |          |

Median, quartiles, P values, and correlation coefficients (r) are shown. * Measured in frozen BMNC. \(^1\) Measured in fresh BMNC.

Table 4. Correlation between NK and LAK Cell Activity and Lymphocyte Subsets in Peripheral Blood

|                      | % of CD16\(^*\) cells | % of CD56\(^*\) cells | % of CD16\(^*\)CD56\(^*\) cells | % of CD16\(^*\)CD8\(^*\) cells | % of CD8\(^*\) cells | % of CD4\(^*\) cells |
|----------------------|------------------------|------------------------|----------------------------------|--------------------------------|----------------------|---------------------|
| NK cell activity     | (C) P <0.001 p = 0.006 | P <0.001 p = 0.06 | P = 0.9 p = 0.06 | P = 0.06 p = 0.002 | P = 0.007 p = 0.04 | P = 0.006 p = 0.006 |
| (unstimulated)       | r = 0.39 r = 0.27 r = 0.36 r = -0.01 r = -0.19 r = -0.31 | P <0.001 P <0.001 P <0.001 P = 0.01 P = 0.9 |
| (P)                  | r = 0.23 r = 0.33 r = 0.40 r = 0.06 r = -0.09 r = 0.00 | |
| NK cell activity     | (C) P = 0.001 P = 0.03 P <0.001 P = 0.2 P = 0.007 P = 0.004 | P <0.001 P <0.001 P <0.001 P = 0.2 P = 0.06 P = 0.4 |
| (IL-2 stimulated)    | r = 0.33 r = 0.22 r = 0.36 r = -0.12 r = -0.27 r = -0.29 | P <0.001 P <0.001 P <0.001 P = 0.2 P = 0.06 P = 0.4 |
| (P)                  | r = 0.25 r = 0.34 r = 0.41 r = 0.08 r = -0.12 r = 0.05 | |
| NK cell activity     | (C) P <0.001 P = 0.02 P <0.001 P = 1.0 P = 0.008 P = 0.006 | P <0.001 P <0.001 P <0.001 P = 0.1 P <0.001 P = 0.03 |
| (IFN-\(\alpha\) stimulated) | r = 0.43 r = 0.23 r = 0.37 r = -0.00 r = -0.27 r = -0.28 | |
| (P)                  | r = 0.26 r = 0.36 r = 0.44 r = 0.11 r = -0.22 r = 0.15 | |
| LAK cell activity    | (C) P = 0.2 P = 0.4 P = 0.4 P = 0.6 P = 0.9 P = 0.1 | P <0.001 P <0.001 P <0.001 P = 0.1 P = 0.3 P = 0.2 |
| (P)                  | r = 0.14 r = 0.08 r = 0.08 r = 0.04 r = -0.01 r = -0.16 | P <0.001 P <0.001 P <0.001 P = 0.1 P = 0.3 P = 0.2 |
|                      | r = 0.12 r = 0.29 r = 0.29 r = -0.14 r = -0.07 r = 0.08 | |

Results of correlation analyses P values and correlation coefficients (r) are shown. All NK/LAK cell activities are at an E/T ratio 50:1. * Measured in fresh BMNC for patients and in frozen BMNC in controls.
Table 5. Correlation between NK and LAK Cell Activity and HIV Antigen Titer, β₂-Microglobulin, IgG, IgA, and IgM in Plasma of HIV-infected Patients

| HIV antigen titer | β₂-Microglobulin | IgG | IgA | IgM |
|-------------------|------------------|-----|-----|-----|
| NK cell activity  |                  |     |     |     |
| (unstimulated)    | P = 0.8          | P = 0.4 | P = 0.4 | P = 0.2 | P = 0.9 |
|                   | r = 0.01         | r = -0.06 | r = -0.06 | r = 0.07 | r = 0.01 |
| NK cell activity  |                  |     |     |     |
| (IL-2 stimulated) | P = 0.9          | P = 0.2 | P = 0.2 | P = 0.7 | P = 0.9 |
|                   | r = 0.00         | r = -0.08 | r = -0.09 | r = 0.02 | r = 0.01 |
| NK cell activity  |                  |     |     |     |
| (IFN-α stimulated)| P = 0.7          | P = 0.002 | P = 0.1 | P = 0.4 | P = 1.0 |
|                   | r = -0.04        | r = -0.21 | r = -0.10 | r = -0.06 | r = 0.00 |
| LAK cell activity |                  |     |     |     |
|                   | P = 0.4          | P = 0.002 | P = 0.1 | P = 0.4 | P = 0.7 |
|                   | r = -0.05        | r = -0.19 | r = -0.10 | r = -0.05 | r = -0.02 |

Results of correlation analyses P values and correlation coefficients (r) are shown. ND, not done. All NK/LAK cell activities are at E/T ratio 50:1.

no differences in concentrations of CD56⁺ and CD16⁻CD56⁺ cells between these two patient groups (data not shown).

Correlation Analysis. For patients, an inverse correlation was found between the percentage of CD4⁻ cells and percentages of all NK cell subtypes and CD8⁺ cells, whereas there was no correlation between the percentage of CD4⁺ cells and the total number of any NK cell subtypes or CD8⁺ cells, (Table 3) and no correlation between the percentage of CD4⁺ cells and the proportions of CD16⁺ NK cells coexpressing CD8 or CD56 (data not shown). The percentage of CD4⁺ cells correlated to percentage and total number of CD3⁺ cells (Table 3).

To examine the mechanisms behind the suppressed NK and LAK cell activity in patients, the unstimulated NK cell activity E/T ratio 50:1, the IL-2- and IFN-α-stimulated NK cell activity, and the LAK cell activity E/T ratio 50:1 were correlated to proportions of the different NK cell subsets (CD16⁺, CD56⁺, CD56⁻CD16⁺, CD16⁺CD8⁻) for patients and controls (Table 4). A positive correlation was found between the unstimulated as well as the IL-2- and IFN-α-stimulated NK cell activity and the percentages of CD16⁺, CD56⁺, and CD16⁺CD56⁺ cells in both groups, whereas there was no correlation to the percentage of CD16⁺CD8⁻ cells in either group. In the controls, the LAK cell activity did not correlate to any of the NK cell subsets. In the patients, the LAK cell activity positively correlated to the percentages of CD56⁻ cells and CD16⁻CD56⁺ cells (Table 4).

In patients, a weak positive correlation was found between IFN-α-stimulated NK cell activity and the percentage of CD4⁺ cells (r = 0.15), whereas the unstimulated NK cell activity E/T ratio 50:1, the IL-2-stimulated NK cell activity, and the LAK cell activity E/T ratio 50:1 did not correlate to the percentage of CD4⁺ cells (Table 4). The relationships between NK/LAK cell activity and the percentage of CD4⁺ cells were analyzed separately in patients with AIDS and patients without AIDS. In non-AIDS patients, the IFN-α-stimulated NK cell activity did correlate with the percentage of CD4⁺ cells (r = 0.19, P = 0.009); this correlation, however, was not found in AIDS patients (data not shown). The unstimulated and IL-2-stimulated NK cell activity and the LAK cell activity did not correlate to the percentage of CD4⁺ cells in neither group (data not shown). The unstimulated NK cell activity per NK cell (LU₁₅/10⁶ CD16⁺ cells and LU₁₅/10⁶ CD56⁺ cells) did not correlate with the percentage of CD4⁺ cells in patients (data not shown). In contradiction to this, a negative correlation was found between the NK cell activity, either unstimulated or stimulated by IL-2 or IFN-α, and the percentage of CD4⁺ cells in controls, whereas no correlation was found between LAK cell activity and the percentage of CD4⁺ cells (Table 4).

The NK cell activity, either unstimulated or stimulated with IL-2 or IFN-α, and the LAK cell activity did not correlate to the HIV antigen titer, IgG, IgA, or IgM in controls (Table 5). A weak inverse correlation was found between β₂-microglobulin titer and IFN-α-stimulated NK cell activity or LAK cell activity (r = -0.21 vs r = -0.19; Table 5).

The relationship of NK/LAK cell activity with other parameters was further analyzed in patients with AIDS and patients without AIDS, as well as in controls, by means of multiple linear regression. The square roots of the unstimulated NK cell activity (E/T ratio 50:1), the IL-2- and IFN-α-stimulated NK cell activity, and the LAK cell activity (E/T ratio 50:1) were included in the models as dependent parameters in patients and controls. The square roots of the dependent parameters were used to obtain normal distribution of the
Table 6. Analysis of NK/LAK Cell Activity by Multiple Linear Regression

| Independent variable | Dependent variables | Coefficients of dependent variables | P values of dependent variables |
|----------------------|---------------------|-------------------------------------|---------------------------------|
| NK cell activity     |                     |                                     |                                 |
| (unstimulated)       | % of CD4<sup>+</sup> cells | -0.028 ± 0.018                     | 0.1                             |
|                      | % of CD16<sup>+</sup> cells | 0.069 ± 0.025                      | 0.007                           |
|                      | % of CD56<sup>+</sup> cells | 0.030 ± 0.040                      | 0.5                             |
|                      | % of CD4<sup>+</sup> cells | 0.018 ± 0.010                      | 0.08                            |
|                      | % of CD16<sup>+</sup> cells | 0.014 ± 0.014                      | 0.2                             |
|                      | % of CD56<sup>+</sup> cells | 0.071 ± 0.015                      | 0.00001                         |
| (IL-2 stimulated)    | % of CD4<sup>+</sup> cells | -0.006 ± 0.027                     | 0.8                             |
|                      | % of CD16<sup>+</sup> cells | -0.040 ± 0.022                     | 0.07                            |
|                      | % of CD56<sup>+</sup> cells | 0.058 ± 0.025                      | 0.02                            |
| (IFN-α stimulated)   | % of CD4<sup>+</sup> cells | -0.032 ± 0.023                     | 0.2                             |
|                      | % of CD16<sup>+</sup> cells | 0.072 ± 0.031                      | 0.02                            |
|                      | % of CD56<sup>+</sup> cells | 0.027 ± 0.052                      | 0.6                             |
|                      | % of CD4<sup>+</sup> cells | 0.038 ± 0.014                      | 0.07                            |
|                      | % of CD16<sup>+</sup> cells | 0.015 ± 0.019                      | 0.4                             |
|                      | % of CD56<sup>+</sup> cells | 0.078 ± 0.020                      | 0.0002                          |
| (A)                  | % of CD4<sup>+</sup> cells | -0.029 ± 0.041                     | 0.5                             |
|                      | % of CD16<sup>+</sup> cells | -0.043 ± 0.032                     | 0.2                             |
|                      | % of CD56<sup>+</sup> cells | 0.092 ± 0.047                      | 0.06                            |
| NK cell activity     | % of CD4<sup>+</sup> cells | -0.024 ± 0.021                     | 0.3                             |
| (IFN-α stimulated)   | % of CD16<sup>+</sup> cells | 0.097 ± 0.030                      | 0.002                           |
|                      | % of CD56<sup>+</sup> cells | 0.015 ± 0.050                      | 0.8                             |
|                      | % of CD4<sup>+</sup> cells | 0.058 ± 0.014                      | 0.00004                         |
|                      | % of CD16<sup>+</sup> cells | 0.021 ± 0.019                      | 0.3                             |
|                      | % of CD56<sup>+</sup> cells | 0.100 ± 0.020                      | <0.00001                        |
|                      | % of CD4<sup>+</sup> cells | -0.018 ± 0.038                     | 0.6                             |
|                      | % of CD16<sup>+</sup> cells | -0.055 ± 0.029                     | 0.2                             |
|                      | % of CD56<sup>+</sup> cells | 0.067 ± 0.043                      | 0.1                             |
| LAK cell activity    | % of CD4<sup>+</sup> cells | -0.025 ± 0.019                     | 0.2                             |
|                      | % of CD16<sup>+</sup> cells | 0.006 ± 0.029                      | 0.8                             |
|                      | % of CD56<sup>+</sup> cells | 0.019 ± 0.044                      | 0.7                             |
|                      | % of CD4<sup>+</sup> cells | 0.038 ± 0.016                      | 0.05                            |
|                      | % of CD16<sup>+</sup> cells | -0.026 ± 0.021                     | 0.2                             |
|                      | % of CD56<sup>+</sup> cells | 0.121 ± 0.023                      | <0.00001                        |
residuals. The dependent variables in each group were the percentages of CD4⁺, CD16⁺, and CD56⁺ cells. In patients, the following additional independent parameters were included in the model: HIV antigen titer, IgA, IgG, IgM, and β₂-microglobulin. These additional dependent parameters were all insignificant in models including the percentages of CD4⁺, CD16⁺, and CD56⁺ cells. It appears from Table 6 that regarding the NK cell activity in controls (unstimulated or stimulated by IL-2 or IFN-α), the percentage of CD16⁺ cells contributed the most to the variation in cytotoxicity, whereas the percentages of CD56⁺ and CD4 cells were without significant effect. However, in patients without AIDS, the percentage of CD56⁺ cells, not the percentage of CD16⁺ cells, explained the variation in cytotoxicity (Table 6). In patients without AIDS, the percentage of CD4⁺ cells also had a significant effect on the IFN-α-stimulated NK cell activity and the LAK cell activity (Table 6). In AIDS patients, however, the percentages of CD4⁺ and CD16⁺ cells had no influence on NK/LAK cell activity, whereas the percentage of CD56⁺ cells had a significant effect on the unstimulated NK cell activity, but no influence on the stimulated NK and LAK cell activities (Table 6).

In patients, a strong correlation was found between the LAK cell activity and the NK cell activity, either unstimulated or stimulated with IFN-α or IL-2 (r = 0.46, P < 0.001, r = 0.58, P < 0.001, r = 0.53, P < 0.001, respectively; E/T ratio 50:1), whereas in controls, this correlation was weaker (r = 0.27, P = 0.009, r = 0.32, P = 0.002, r = 0.39, P < 0.001, respectively).

Discussion

Knowledge about the percentual distribution of NK cells among BMNC is important to evaluate the functional in vitro NK cell activity (lysis per fixed number of BMNC in HIV-seropositive subjects must be caused by a defective lytic capacity of each NK cell, as suggested by others (5, 8, 11, 21). Pearson correlation analysis revealed that the NK cell activity correlated to the percentages of CD16⁺, CD56⁺, and CD16⁺CD56⁺ cells in patients and controls, but not to the CD16⁺CD8⁺ cell subgroup, which is in line with the assumption that the majority of human NK cell activity is mediated by the CD16⁺, CD56⁺, and CD16⁺CD56⁺ cells (18). However, through multiple linear regression, it was concluded that in controls, the percentage of CD16⁺ cells was the only parameter tested with any significant effect on NK cell activity, whereas in patients, the percentage of CD16⁺ cells had almost no effect on NK cell activity. These results could indicate that a specific defect exists in the CD16⁺ cell population in subjects with HIV infection. If the cytotoxic function of these cells declines, the importance of the CD56⁺ cells increases. This could explain the finding that the LAK cell activity correlated to the percentages of CD56⁺ and CD16⁺CD56⁺ cells only in the patient group. However, others have reported a correlation in LAK cell activity to the percentage of CD56⁺ cells in HIV-seropositive patients, as well as in healthy HIV-seronegative individuals (13), but since the percentage of CD56⁺ cells was not decreased in the present study's patients, low fractions of this subpopulation could not explain the depressed in vitro LAK cell activity in HIV infection.

Our findings agree with studies showing normal percentages of CD16⁺ (10) or CD56⁺ cells (13), whereas others have shown that the percentages of CD16⁺ and CD16⁺CD8⁺ NK cells were low in HIV-seropositive subjects (6, 22). The function of NK cells in HIV-seropositive subjects differed from that of controls in their responsiveness to IFN-α. The patients' NK cells were boosted with IFN-α to a lesser degree than cells of controls, in accordance with previous studies (8, 23), whereas IL-2 boosted the NK cell activity to the same degree in both groups, but without restoration of the defective cytotoxic activity in patients as suggested by others (9, 11). It has been suggested that a serum factor contributes to the suppression of the NK and LAK cell functions, but this factor has not been fully identified (16, 24, 25). Our study showed that there was no correlation between

### Table 6. Continued

| Independent variable | Dependent variables | Coefficients of dependent variables | P values of dependent variables |
|----------------------|---------------------|-------------------------------------|-------------------------------|
| (A)                  | % of CD4⁺ cells     | -0.037 ± 0.047                      | 0.4                           |
| % of CD16⁺ cells     | 0.000 ± 0.038       | 1                                   |
| % of CD56⁺ cells     | 0.013 ± 0.050       | 0.8                                 |

Results of multiple linear regression: parameters included in models, their coefficients ± SE, and P values of the parameters in F test are shown. Independent variables were transformed by taking the square root before they were included in the models. All NK/LAK cell activities are at E/T ratio 50:1.
NK cell activity and concentrations of immunoglobulins or HIV antigen in serum.

Some studies have shown that the NK (8) and LAK (16) cell activities in HIV-seropositive subjects decrease with disease progression. Others were unable to show differences in cytotoxicity between AIDS-related complex and AIDS patients (10, 11). Our study showed that NK cell activity, either unstimulated or stimulated, and LAK cell activity did not differ between the AIDS group and the non-AIDS group. Furthermore, the NK and LAK cell activities did not differ between patients with disseminated CMV infection, malignant lymphoma, or Kaposi’s sarcoma, compared to those without these AIDS-defining disorders. However, when the CDC classification system was used, it revealed a difference between CDCII + III and CDCIV in IFN-α-stimulated NK cell activity and LAK cell activity. The interpretation of these results is that the defect in these two forms of stimulated cytotoxicity is progressive until the early symptomatic stage of HIV infection, whereas no further progression is seen by the onset of overt AIDS. In line with these observations, there was a positive effect on IFN-α-stimulated NK cell activity and LAK cell activity by the percentage of CD4+ cells in multiple linear regression in patients without AIDS. None of the other classical progression markers, including IgG, IgA, HIV antigen, and β2-microglobulin were of any importance for NK/LAK cell activity when tested in a model including the percentages of CD4+, CD16+, and CD56+ cells. This, combined with the fact that the effect of the percentage of CD4 cells on NK/LAK cell activity is only seen in patients, indicates that the loss of CD4+ cells could have a direct influence on the decrease in NK/LAK cell activity in HIV infection. The fact that IFN-α-stimulated NK cell activity and LAK cell activity are correlated to the percentage of CD4+ cells and are different between CDCII+III and CDCIV NK cell activity indicates that the defect in HIV disease of these two measures of natural immunity is more specific and of greater importance compared to, e.g., the unstimulated and IL-2-stimulated NK cell activity. Not only the loss of CD4+ cells, but also changes in the function of these cells, could contribute to the defective natural immunity in HIV disease. The important finding of an imbalance in the Th1- and Th2-type responses that contribute to the loss of T cell response to recall antigens and, finally, loss of reactivity to mitogens (26) may be extended to also include a loss of non-MHC-restricted cytotoxic activity.

The finding of a lower CD16+ cell count in patients compared to controls is in accordance with the findings of Mansour et al. (6). However, the finding that the concentration of the CD16+CD8+ subgroup was elevated in patients compared to controls is in contrast to the findings by Mansour et al. (6), who described a selective depletion of this subgroup. In accordance with previous findings (6, 8) all the NK cell subsets had a higher percentage, but a lower total cell count in the AIDS group compared to the non-AIDS group. The mechanisms behind the loss or decreased production of NK cells are not understood. It has been suggested that HIV can infect NK cells (7, 27, 28), whereas other studies report only nonproductive HIV infection of NK cells (29). Active in vitro HIV infection of NK cells after infection with human herpesvirus 6 has been described (30). The present study shows that the lower NK cell count is determined by a lower total lymphocyte count in the AIDS patients. This might be related to a weakened bone marrow function in AIDS patients (reviewed in 31).

The results presented in this paper have been obtained by the use of frozen cells. Since freezing did not affect the FACScanaylisis of lymphocyte subsets, and since it had the same effect on NK cell activity in patients and controls, as well as in AIDS and non-AIDS patients, it is unlikely that the conclusions of this paper are to any major extent influenced by the use of frozen cells.

We conclude that the non-MHC-restricted cytotoxicity is impaired in HIV patients primarily because of a qualitative defect of the NK and LAK cells. This study clearly shows an early defect in NK/LAK cell activity in HIV infection, which for the unstimulated NK cell activity, does not progress by onset of symptoms. However, the defect in IFN-α-stimulated NK and LAK cell activities is, however, progressive until the onset of symptoms, and it is related to the loss of CD4+ cells.

We thank Ruth Rousing, Hanne Willumsen, Gitte Pedersen, Lone Jensen, and Åse Stricker for excellent technical assistance. We are also grateful to Peter Dalgaard from the Department of Biostatistics at the University of Copenhagen for valuable discussion.

This study was supported by the AIDS Foundation (Copenhagen).

Address correspondence to Bente Klarlund Pedersen, Department of Infectious Diseases M7721, Rigshospitalet, Tegnevej 20, DK-2200 Copenhagen N, Denmark.

Received for publication 20 September 1994 and in revised form 20 March 1995.

References

1. Rosenberg, Z.F., and A.S. Fauci. 1990. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol. Today. 11:176–180.
2. Fauci, A.S. 1984. Immunologic abnormalities in the acquired

798 Defective Natural Immunity: An Early Manifestation of HIV Infection
immunodeficiency syndrome (AIDS). Clin. Res. 32:491-499.

3. Fauci, A.S. 1988. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science (Wash. DC). 239:617-622.

4. Brenner, B.G., A. Dascal, R.G. Margoolese, and M.A. Wainberg. 1989. Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J. Leukoc. Biol. 46:75-83.

5. Scott Alagara, D., F. Vuillier, A. Cayota, and G. Dighiero. 1992. Natural killer (NK) cell activity during HIV infection: a decrease in NK activity is observed at the clonal level and is not restored after in vitro long-term culture of NK cells. Clin Exp Immunol. 90:181-187.

6. Mansour, I., C. Doi, and P. Rouger. 1990. CD16+ NK cells decrease in all stages of HIV infection through a selective depletion of the CD16+CD8−CD3− subset. AIDS Res. Hum. Retroviruses. 6:1451-1457.

7. Siranni, M.C., F. Tagliaferri, and F. Aiuti. 1990. Pathogenesis of the natural killer cell deficiency in AIDS. Immunol. Today. 11:81-82.

8. Cai, Q., X.L. Huang, G. Rappocciolo, and C.R.J. Rinaldo. 1992. Alterations in cyto toxic and phenotypic subsets of natural killer cells in acquired immune deficiency syndrome (AIDS). J. Clin. Immunol. 7:16-23.

9. Bonavida, B., J. Katz, and M. Gottlieb. 1986. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL-2. J. Immunol. 137:1157-1163.

10. Katz, J.D., R. Mitsuysu, M.S. Gottlieb, L.T. Lebow, and B. Bonavida. 1987. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytoxicity. J. Immunol. 139:55-60.

11. Brenner, B.G., C. Gryllis, M. Gornitsky, and M.A. Wainberg. 1993. Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol. 93:142-148.

12. Chiu, T.W., S. Plaeger Marshall, A. Haas, B.J. Ank, and E.R. Stiehm. 1989. Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndrome. Clin. Immunol. Immunopathol. 53:449-459.

13. Brenner, B.G., C. Gryllis, and M.A. Wainberg. 1991. Role of antibody-dependent cellular cytoxicity and lymphokine-activated killer cells in AIDS and related diseases. J. Leukoc. Biol. 50:628-640.

14. Cauda, R., M. Tumbarello, L. Ortona, R.C. Kennedy, K.R. Shuler, T.C. Chanh, and P. Kanda. 1990. Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides. Nat. Immun. Cell Growth Regul. 9:366-375.

15. Gryllis, C., M.A. Wainberg, M. Gornitsky, and B. Brenner. 1990. Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders. AIDS (Phila.). 4:1205-1212.

16. O'Shea, J., and J.R. Orfardo. 1992. The biology of natural killer cells: insights into the molecular basis of function. In The Natural Killer Cell. C.E. Lewis and J.O. McGee, editors. Oxford University Press, Oxford. pp. 1-40.

17. Welsh, R.M. 1986. Regulation of virus infections by natural killer cells. A review. Nat. Immun. Cell Growth Regul. 5:169-199.

18. Grimm, E.A., A. Mazumder, H.Z. Zhang, and S.A. Rosenberg. 1982. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J. Exp Med. 155:1823-1841.

19. Siranni, M.C., S. Soddu, W. Malorni, G. Arancia, P. Aiuti, and S.S. Soddu. 1988. Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin. J. Immunol. 140:2565-2568.

20. Vuillier, F., N.E. Bianco, L. Montagnier, and G. Dighiero. 1988. Selective depletion of low-density CD8+, CD16+ lymphocytes during HIV infection. AIDS Res. Hum. Retroviruses. 4:121-129.

21. Voth, R., S. Rossol, E. Graff, H.P. Laubenbacher, H.C. Schroeder, W.E. Muller, K.H. Meyer zum Buschenfelde, and G. Hess. 1988. Natural killer cell activity as a prognostic parameter in the progression to AIDS [letter]. J. Infect. Dis. 157:851-852.

22. Vulcano, M., S.E. Olubuenaga, N. Galasi, M. Felippo, R. Perez Bianco, and M.M. de Bracco. 1993. Inhibition of normal natural killer cytotoxicity by sera from hemophiliac patients. Immunol. Lett. 36:153-159.

23. Oh, S.K., S. Cerda, B.G. Lee, G.C. Blanchard, J.E. Walker, and K. Hartshorn. 1993. Partial purification and identification of an immunosuppressive factor in AIDS sera. AIDS Res. Hum. Retroviruses. 9:365-373.

24. Clerici, M., and G.M. Shearer. 1993. A TH1/TH2 switch is a critical step in the etiology of HIV infection. Immunol. Today. 14:190-191.

25. Chehimi, J., S. Bandyopadhyay, K. Prakash, B. Perussia, N.F. Hassan, H. Kawashima, D. Campbell, J. Kornbluth, and S.E. Sturz. 1993. In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates. J. Virol. 65:1812-1822.

26. Toth, F.D., P. Mosborg Petersen, J. Kiss, G. Abaogyo Mathiesen, M. Zdjarekovic, H. Hager, and P. Ebbesen. 1993. Differential replication of human immunodeficiency virus type 1 in CD8− and CD8+ subsets of natural killer cells: relationship to cytokine production pattern. J. Virol. 67:5879-5888.

27. Scott Alagara, D., F. Vuillier, A. Cayota, V. Rame, D. Guetard, E.W. Muller, J. Kornbluth, and G. Hess. 1993. In vitro non-productive infection of purified natural killer cells by the BRU isolate of the human immunodeficiency virus type J. Virol. 67:753-757.